Genascence
Developing revolutionized life changing gene therapies for prevalent musculoskeletal and joint diseases.
Launch date
Employees
Market cap
-
Enterprise valuation
$42—63m (Dealroom.co estimates May 2022.)
Palo Alto California (HQ)
Date | Investors | Amount | Round |
---|---|---|---|
* | N/A | Spinout | |
* | $10.5m | Series A | |
* | $11.6m | Grant | |
Total Funding | $22.1m |